BPCIA & FDA Steps as Article III Standing from the PTAB?
Are Biosimilar Development Efforts Enough? In Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Co. ( here ), the Federal Circuit was poised to explore the level of biosimilar legwork that could satisfy Article III standing for appeal from an adverse…
February 8, 2019PTAB2 min read